NS-PARK launches Master Trial, France's first clinical trial platform to accelerate the identification of neuroprotective treatments for Parkinson's disease

At a time when Parkinson's disease affects almost 11 million people worldwide, and its prevalence could more than double by 2050, the NS-PARK clinical research network is launching Master Trial, the first French clinical trial platform dedicated to neurodegenerative diseases. This innovative project aims to accelerate the identification of neuroprotective treatments for Parkinson's disease by simultaneously testing several promising drug candidates. Led by the AP-HP, Master Trial is supported by the public authorities, the F-CRIN clinical research infrastructure, the Association France Parkinson, the Toulouse University Hospital and major national and international players.